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AbstrACt
Introduction Anti- platelet therapy, angiotensin- converting 
enzyme inhibitors/angiotensin II receptor blockers, beta- 
blockers and statins are cost- effective in patients with 
atherosclerotic cardiovascular diseases (ASCVD) for 
reducing the risk of ASCVD events. Unfortunately, there is 
abundant evidence that adherence to these cardiovascular 
medications is far from ideal. A recent Cochrane review 
showed a potential beneficial effect of Short Message 
Service (SMS) interventions on adherence to medication in 
ASCVD patients.
Methods and analysis The txt2heart study is a pragmatic 
randomised single- blind controlled trial. The objective is 
to evaluate the efficacy and safety of an intervention with 
SMS messages delivered by mobile phones to improve 
adherence to cardiovascular medications in patients 
with ASCVD. The intervention consists of behavioural 
techniques delivered via SMS. The primary outcome is 
change in blood serum low- density lipoprotein cholesterol 
levels as an indicator of adherence to statins. Secondary 
outcomes will include systolic blood pressure as an 
indicator of adherence to blood- lowering therapies 
and heart rate as an indicator of adherence to beta- 
blockers, urine levels of 11- dehydrothromboxane B2, 
self- reported adherence to cardiovascular medications 
and rates of cardiovascular death or hospitalisation due to 
cardiovascular disease.
Ethics and dissemination The study will be performed 
in compliance with the protocol, regulatory requirements, 
Good Clinical Practice and ethical principles of the 
Declaration of Helsinki. The Ethics Committee of Fundación 
Cardiovascular de Colombia evaluated and approved the 
trial. The txt2heart Colombia trial aims to provide robust 
evidence to evaluate whether SMS messages delivered 
through mobile telephones change the behaviour of 
Colombian patients who have suffered a cardiovascular 
event. Trial results will be presented to the local health 
authorities, and if the intervention is effective and safe, we 
hope this strategy will be implemented quickly because of 
its low cost and wide- reaching impact on the population.
trial registration number NCT03098186.
IntroduCtIon
Atherosclerotic cardiovascular diseases 
(ASCVD) are the main cause of death world-
wide. Approximately 35 million people 
worldwide have an acute coronary event or 
cerebrovascular event annually, and one- 
quarter of these events occur in people with 
established ASCVD.1 These arterial occlu-
sive events occur at an early age in low- and 
middle- income countries (LMICs), which 
affects economically active populations and 
results in large economical impacts.2
Evidence from randomised controlled 
trials (RCTs) demonstrated that anti- platelet 
therapy, angiotensin- converting enzyme 
(ACE) inhibitors/angiotensin II receptor 
blockers (ARB), beta- blockers and statins are 
cost- effective in reducing the risk of ASCVD 
events in patients with established ASCVD, 
and these agents are included in the list of 
the WHO Essential Medicines List.3 Treat-
ment with these four proven medications 
strengths and limitations of this study
 ► The trial uses an innovative intervention through 
Short Message Service (SMS) methodology based 
on behaviour theories.
 ► The trial uses biomarkers to evaluate medication 
adherence.
 ► The trial is the largest evaluating SMS to increase 
adherence for cardiovascular secondary prevention.
 ► The trial uses an innovative intervention through 
SMS methodology based on behaviour theories.
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(together with smoking cessation) prevents or postpones 
approximately 75% to 80% of recurrent vascular events 
and their complications, such as death and disability.4
Unfortunately, there is abundant evidence that the 
worldwide adherence to these cardiovascular medications 
in patients with ASCVD is far from ideal. Less than half 
of patients with known ASCVD disease in high- income 
countries are receiving this group of cardiovascular medi-
cations, and the situation is much worse in LMICs. The 
PURE study showed that only 1 in 20 patients with ASCVD 
in LMICs are receiving the four types of cardiovascular 
drugs.5
A wide range of socio- economic and service level factors 
influence whether patients obtain medications, including 
the availability of medication (drugs out of stock), the 
lack of affordable medication and service factors, such 
as the availability and training of healthcare providers. 
Adherence to medication focuses on whether patients 
take the prescribed medication. Two recent systematic 
reviews on patient factors that affect adherence to ASCVD 
medications in secondary prevention showed that these 
factors go far beyond simply ‘forgetting’ to take the 
medication and include a range of factors, including 
patients’ perceptions of the cause and prognosis of the 
illness (eg, fatalistic perceptions or absence of symptoms) 
and/or the risks and benefits of medications (eg, fear of 
side effects or concern about multiple medications), the 
patient- physician relationship, availability of family/social 
network support and comorbidities (eg, depression).6 7
A recent systematic review from RCTs on interven-
tions to improve adherence to medications in patients 
with ASCVD demonstrated several potential interven-
tions, and importantly, simple interventions may be as 
effective as complex ones (and therefore easier to repli-
cate).8 However, this review also highlighted many limita-
tions in the current evidence, such as risk of bias, small 
sample sizes and lack of studies in LMICs, where most 
of the patients with ASCVD live. Among the most prom-
ising simple strategies to increase adherence, this review 
singled out Short Message Service (SMS) interventions.
Mobile phones have become an ‘essential’ instrument 
of daily life worldwide, with approximately 7 billion 
subscribers, of whom 78% are based in LMICs.9 This use 
makes mobile phones an ‘ideal instrument’ to deliver 
health behaviour change interventions to large numbers 
of people at a low cost. Systematic reviews of RCTs using 
mHealth interventions confirm that SMS can be successful 
in changing behaviour, including smoking cessation and 
improved adherence to HIV medications.10 11 Patient 
factors influencing adherence, such as knowledge atti-
tudes and beliefs, could be amenable to change using 
mobile phone messages sent to patients.
A recent Cochrane review evaluated the effects of SMS 
on adherence to medications in patients with ASCVD.12 
The review identified seven trials (1310 participants) and 
showed a beneficial effect of SMS on adherence to medi-
cations in six of these trials. However, the quality of the 
evidence was very low. The Cochrane review identified the 
following limitations: (I) trials of small sample size (34 to 
521 participants); (II) most trials had a short follow- up 
(<6 months); (III) primary outcomes reported were of 
limited clinical relevance; (IV) most studies recruited 
only patients with acute coronary syndrome, which leaves 
out an important group of patients with other arte-
rial occlusive events (eg, ischaemic stroke, peripheral 
vascular disease and programmed coronary revasculari-
sations) who should be amenable for this type of inter-
vention; (V) few studies were performed in LMICs and 
(VI) most trials did not describe the processes behind 
the SMS content generation, and the few trials that did 
report these processes did not target the key knowledge 
and attitudinal factors that are known to influence adher-
ence to medication; instead the interventions were simple 
‘reminders’.
In conclusion, given the high prevalence of people 
with ASCVD in LMICs and the low use of cost- effective 
secondary prevention medications, a low- cost interven-
tion that builds on a ubiquitous technology in LMICs, 
such as mobile phones, has the potential to improve 
public health. The current evidence shows that SMS 
interventions based on behaviour- change techniques are 
a potentially effective strategy to increase adherence to 
medications in people with ASCVD. However, further 
large trials are needed.
To provide the high- quality evidence needed to assess 
the effect of SMS interventions based on behaviour- 
change techniques to increase adherence to medications 
in patients with ASCVD, we designed the txt2heart study, 
which is a large pragmatic superiority parallel randomised 
single- blind controlled trial with a 1:1 allocation ratio to 
evaluate the efficacy and safety of SMS on adherence to 
cardiovascular medications. The trial is being performed 
in a setting (Colombia) where patient factors, such as 
knowledge, attitudes and beliefs, are important deter-
minants of adherence. In this context, medicines are 
widely available and generally affordable, so an interven-
tion delivered to patients via SMS has the potential to be 
effective.
MEthods And AnAlysIs
This protocol is reported following the Standard Protocol 
Items: Recommendations for Interventional Trials13 (see 
online supplementary file 1).
Aim and objectives
The primary objective is to evaluate the efficacy and 
safety of an intervention with SMS messages delivered by 
mobiles phones to improve adherence to cardiovascular 
medications in patients with ASCVD. We will assess the 
intervention efficacy via the measurement of blood serum 
low- densitylipoprotein cholesterol (LDL- C) levels as an 
indicator of adherence to statins, systolic blood pressure 
as an indicator of adherence to blood- lowering therapies 
(ACE inhibitors or ARBs) and heart rate as an indicator 
of adherence to beta- blockers.
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The secondary objective is to assess the impact of mobile 
text messaging on self- reported adherence to medica-
tions, hospitalisations and the composite endpoint of inci-
dent major adverse cardiovascular events at 12 months.
Choice of comparator
The trial design is a two- parallel arm in which the 
comparator is a control follow- up. Patients allocated to 
the control group will receive monthly messages that 
convey the gratitude of the research team for their partic-
ipation and emphasise the importance of follow- up. The 
choice of comparator was guided by considerations of 
enhancing acceptability of the trial and enhancing reten-
tion and follow- up rates, while not materially altering 
medication- taking behaviours or causing participants 
harm or discomfort. Participants will be told that they 
could be allocated to one of two different groups. Further-
more, our intervention will not interfere with medical 
treatment. Patients will be warned that the study does not 
replace medical assistance and that they must continue 
with their traditional treatment.
Trial design
Txt2heart Colombia is a two- parallel arm, single- blind 
individually randomised controlled trial. This design 
is aimed to minimise any potential bias that affects the 
internal validity of the study. The selection criteria were 
designed to increase the number of potential beneficia-
ries of the intervention and to keep the selection process 
as close as possible to the future scenario in which the 
intervention will be implemented. Therefore, txt2heart 
Colombia is pragmatic in design. The active interven-
tion will be the SMS delivered to mobile phones, and 
the content of the SMS is aimed to modify behaviours 
associated with poor adherence to ASCVD medications 
in ASCVD patients. Randomisation will be performed as 
block randomisation with a 1:1 allocation.
study setting
We will recruit patients at Fundación Cardiovascular 
de Colombia, which has a staff that is knowledgeable in 
trials and a sufficient pool of eligible patients. The trial 
will continue to add sites, if necessary, to ensure that the 
sample size is achieved. There is no limit to the maximum 
number of patients to be recruited in each site.
Eligibility criteria
Inclusion criteria: Adult patients ≥18 years old with 
a history of at least one of the following arterial occlu-
sive events will be included: acute coronary syndrome 
(unstable angina, acute myocardial infarction with or 
without ST elevation), stable angina, ischaemic cere-
brovascular disease, peripheral arterial disease or coro-
nary revascularisation (coronary artery bypass surgery 
or percutaneous transluminal coronary angioplasty). 
Patients should own a mobile phone and be able to read 
SMS.
Exclusion criteria: Known contraindication to take all 
of the appropriate cardiovascular secondary prevention 
medications.
Intervention
The intervention under evaluation consists of behavioural 
change techniques (BCTs) delivered via SMS. We devel-
oped our intervention following the recommendations of 
Abroms et al.14 First, we reviewed the literature on indi-
vidual level factors that influence adherence to medica-
tion. We performed country- specific qualitative studies 
using focus group discussions and semi- structured inter-
views to evaluate cardiovascular patients’ perceptions 
about mHealth programmes to determine the necessary 
content and preferred timing and frequency of the SMS 
messages. To construct the content of the SMS, we wrote 
messages using educational and enabling behaviour 
change functions and established BCTs to target the 
potentially modifiable factors that influence the adher-
ence referred to in the literature and found in our qual-
itative studies.15 Finally, we tested the SMS messages 
with participants and adapted the messages based on 
their feedback to ensure the messages were understand-
able, acceptable and relevant.16 The resultant inter-
vention delivered by SMS provides information about 
health consequences of adherence or non- adherence, 
instruction on how to take medication, medicine- taking 
prompts and cues, support in establishing medicine- 
taking habits, reframing medicine- taking and provides or 
encourages social support for taking medication.17 The 
messages were designed according to the transtheoret-
ical model (TTM) (Prochaska & DiClemente, 1992) and 
were aimed to enhance actions related to the steps and 
processes of this model. We will send messages daily the 
first month, three times per week the second month and 
once weekly the last 10 months. This reducing frequency 
is consistent with the TTM, which suggests that people 
in the early stages of change require more intense input 
than people in later stages. In accordance with data from 
the focus groups, messages will be sent during working 
hours (08.00 to 18.00 hours). The intervention will be 
delivered through an electronic platform, and it will be 
a one- way intervention. We will explain patients that they 
should not answer the messages, but they will be able to 
request to stop receiving the messages and withdraw from 
the trial by sending a message with the word ‘STOP’. We 
will explain to patients that they should send the ‘stop’ 
message in this situation. Stop messages will be saved 
and monitored by a trained engineer, separate from the 
study team, in order to maintain blinding. Similarly, a 
trained engineer, separate from the study team, will save 
and monitor the patients’ answers if they respond to the 
messages. Because of the pragmatic nature of our study 
we will not tailor the messages. The trial intervention 
will start the day after recruitment and continue for 12 
months or until the participant withdraws from the study 
or dies. The follow- up duration will be at least 12 months 
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Figure 1 Trial flowchart. ASCVD, atherosclerotic 
cardiovascular diseases; LDL- C, low- density lipoprotein 
cholesterol; MARS-5, Medication Adherence Report 
Scale 5; SMS, Short Message Service; 11 dhTxB2, 
11- dehydrothromboxaneB2.
to a maximum of 36 months. Participants will not receive 
messages after month 12.
outcomes
The primary outcome was selected for its clinical rele-
vance and include: differences in changes (12 months 
‘minus’ baseline) in blood serum LDL- C levels as an indi-
cator of adherence to statins.
The following secondary outcomes will be included: 
systolic blood pressure as an indicator of adherence to 
blood- lowering therapies (ACE inhibitors or ARBs), heart 
rate as an indicator of adherence to beta- blockers, urine 
levels of 11- dehydrothromboxaneB2 as an indicator of 
adherence to antiplatelet therapy; self- reported adherence 
to cardiovascular medications used in secondary prevention 
as measured using the Medication Adherence Report 
Scale-5 (MARS-5) questionnaire and rates of cardio-
vascular death or hospitalisation due to cardiovascular 
disease and non- cardiovascular death or hospitalisations 
due to non- cardiovascular disease. We will also include 
road traffic crashes (the only potential known hazard of 
text messaging) and death due to all causes as secondary 
outcomes.
Participant timeline
Participants who fulfil the eligibility criteria and provide 
their informed consent will be recruited into the txt2heart 
trial. After the participant provided informed consent, 
baseline characteristics will be collected at the first visit 
using questionnaires (MARS-5 and Patient Health Ques-
tionnaire-9), blood samples, blood pressure and heart 
rate. Participants will be randomised to the intervention 
or control arm. The trial intervention will start the day 
after recruitment and will continue for 12 months to a 
maximum of 36 months, or when the participant with-
draws from the study, or dies. We will perform a phone 
follow- up interview 3 months later, during the second visit, 
to evaluate adequate SMS delivery and the occurrence of 
clinical events. Finally, we will collect data on self- reported 
adherence to cardiovascular medications (MARS-5), 
blood pressure, heart rate and clinical endpoints in the 
third visit (12 months later). The 12 month follow- up 
marks the primary outcome point. For patients with 
follow- up beyond 12 months, we will perform (by phone) 
assessments of clinical outcomes (death from cardiovas-
cular causes and hospitalisation due to non- fatal acute 
coronary syndrome, non- fatal stroke or urgent revascu-
larisation) every 6 months until 36 months, the longest 
available follow- up (figure 1).
sample size
The sample size of the study is 1600 participants. The 
power of the study was calculated for differences between 
arms in the reduction in the primary outcome LDL- C 
(12 month minus baseline).
The power of the study was calculated for the primary 
outcome of the clinical trial, that is, differences in the 
levels of physiological markers of adherence to cardiovas-
cular drugs.
Because the power of a sample size depends on several 
parameters in this study, such as the doses are finally 
prescribed to patients and what proportion of patients 
will adhere, we performed several power and sample 
size calculations for different scenarios. We concluded 
that 1600 was a reasonable sample size. For example, 
assuming that adherent patients to 40 mg atorvastatin for 
12 months are expected to have an average LDL- C reduc-
tion of 91.3 mg/dL (data derived from randomised clin-
ical trials), and non- adherent patients will reduce LDL- C 
by an average of 18.3 mg/dL (or 20% of the reduction 
in adherent patients) and that the SD of the changes is 
approximately 27.07 mL/dL, we would have 97% power 
to detect a 7% difference in adherence between arms 
or a 77% power to detect a 5% difference (always using 
a 5% type- I error). However, if patients were on 20 mg 
atorvastatin and the expected reductions in LDL- C were 
80.05 mg/dL in adherent and 16.01 mg/dL in non- 
adherent patients, then we would have a 91% power to 
detect a 7% difference of adherence between arms and 
a 66% power to detect a 5% difference between arms 
(table 1).
recruitment
The pragmatic nature of this trial will allow collaborators 
to follow different strategies for participant recruitment 
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Table 1 Sample size calculations
Statins and its frequency in trials
Reduction in LDL after a year of treatment in 
adherents and non- adherents
Power to detect differences 
depending on adherence increase
% AD=yes AD=No Dif 5.0% 7.0% 10.0%
Atorvastatin 10 1.5% 1.79 0.36 1.43 53% 82% 98%
Atorvastatin 20 32.9% 2.07 0.41 1.66 66% 91% 100%
Atorvastatin 40 52.4% 2.36 0.47 1.89 77% 97% 100%
Atorvastatin 80 9.4% 2.64 0.53 2.11 85% 99% 100%
Fluvastatin 20 mg 0.0% 1.02 0.20 0.82 21% 37% 64%
Lovastatin 40 0.0% 1.77 0.35 1.42 53% 81% 98%
Pravastatin 10 0.0% 0.95 0.19 0.76 19% 33% 58%
Pravastatin 20 0.0% 1.17 0.23 0.94 27% 46% 76%
Pravastatin 40 0.0% 1.38 0.28 1.10 35% 60% 88%
Rosuvastatin 5 0.0% 1.84 0.37 1.47 56% 84% 99%
Rosuvastatin 10 0.3% 2.08 0.42 1.66 66% 91% 100%
Rosuvastatin 20 1.7% 2.32 0.46 1.86 76% 96% 100%
Rosuvastatin 40 1.6% 2.56 0.51 2.05 83% 98% 100%
Simvastatin 10 0.0% 1.31 0.26 1.05 32% 55% 85%
Simvastatin 20 0.1% 1.54 0.31 1.23 42% 69% 94%
Simvastatin 40 0.2% 1.78 0.36 1.42 53% 81% 98%
Simvastatin 80 0.0% 2.01 0.40 1.61 63% 90% 100%
Power is calculated assuming a sample size of 800 per arm, 5% type- I error, a SD of LDL change of 0.7 and that non- adherent patients will 
still reduce their LDL on average 20% of the reduction in adherent patients.
Interpretation of the table: Example of third line (atorvastatin 40): 52.4% of patients in the hospital take atorvastatin 40. Adherent patients 
are expected to reduce their cholesterol an average of 2.36 mmol/L in the first year, and non- adherent patients are expected to reduce it 
0.47 mmol/L. If all patients were on atorvastatin 40, we would have a 77% power to detect a true increase in adherence of 5%, a 97% power 
to detect a true increase in adherence of 7% and almost a 100% power to detect a true increase in adherence of 10%. Atorvastatin is the 
most prescribed statin in patients in our study. About the 65% of the sample use.
*Elaborated by the authors.
LDL, low- density lipoprotein.
according to the setting. There are three main approaches 
for the recruitment of patients who fulfil the inclusion 
criteria: (a) in hospital patients at the time of discharge, 
(b) patients attending outpatient clinics and (c) patients 
who are in the healthcare facility database and who will 
be contacted by phone calls and recruited in outpatient 
clinics.
Assignment of intervention
Randomisation: We will use block randomisation (varying 
size), stratifying by centre and with 1:1 allocation between 
the intervention and control arm. Randomisation will 
be performed centrally using the CommCare platform 
after eligibility criteria was confirmed, informed consent 
signed and baseline information collected. Therefore, the 
randomised allocation will not be revealed until after a 
participant was formally entered into the trial. Therefore, 
concealment of allocation will be complete. The SMS will 
be automatically generated by the CommCare platform 
and unknown to the investigators in contact with patients.
Blinding: Because of the nature of the intervention 
(SMS messages), it is not possible to include blind partici-
pants. However, the tx2theart trial will perform a blinded 
assessment of outcomes. Research personnel collecting 
data on clinical events, adherence scales and biomarkers 
will not have access to treatment allocation. The labo-
ratory results will be performed once trial follow- up is 
completed.
data collection methods
Txt2heart Colombia will use Electronic Data Capture. 
These data will be entered in the CommCare platform, 
designed by Dimagi. CommCare is an open source mobile 
platform designed for data collection, client manage-
ment, decision support and behaviour change commu-
nication. The electronic devices (desktop computers, 
laptops and tablets) used in the trial are of exclusive use 
for the txt2heart trial and owned by Fundación Cardiovas-
cular de Colombia.
Our design aims to minimise the reactivity of assess-
ment and the Hawthorne effect, while maximising reten-
tion to follow- up. The following strategies to prevent loss 
to follow- up will be used. (1) One phone call at the third 
month of participation. Trained personnel different from 
the other interviewers will phone the participants to guar-
antee the blind design. Professionals in charge of the 
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follow- up are trained in patient contact with the ability 
to empathise with volunteers. (2) We will register at least 
three relatives’ numbers to contact in case we are not able 
to reach the patient, and we will phone the participant’s 
relatives. (3) We will register the addresses of participants 
in case we cannot reach the patients or the relatives, and 
we will arrange a domiciliary visit. (4) We will share with 
the participants a contact phone number to let us to 
know if they change their phone number contact. We will 
explain these strategies to participants to get permission 
for further contact.
Clinical outcomes
Death from cardiovascular causes and hospitalisation due 
to non- fatal acute coronary syndrome, non- fatal stroke or 
urgent revascularisation will be defined by local investi-
gators based on clinical notes and clear objective criteria 
using the suggestions provided by the 2014 ACC/AHA 
(American Heart Association/American College of Cardi-
ology) Key Data Elements and Definitions for Cardiovas-
cular Endpoint Events in Clinical Trials.18
 Self-reported adherence
To estimate adherence, we will use a self- reported scale 
named MARS-5, which is a valid and reliable scale for 
measuring adherence to medication in chronic conditions 
at trial entry and at the final assessment at 12 months.19 
The MARS-5 elicits patients’ reports of non- adherence. 
To diminish the social pressure on patients to report 
high adherence, items are phrased in a non- threatening 
manner, and patients are assured that their responses will 
be anonymous and confidential. Participants are asked 
to rate the frequency with which they engaged in each 
of five aspects of non- adherent listed behaviours (eg, ‘I 
forget to take these medicines’, ‘I stop taking these medi-
cines for a while’) using a 5- point scale ranging from 
‘never’ to ‘always’. Scores for each item are summed to 
give a total score that ranged from 5 to 25, with higher 
scores indicating higher levels of adherence. Patients will 
be recruited at least 30 days, after discharge in the case of 
their first cardiovascular event. A trained psychologist will 
administer the MARS-5 during the first interview.
In order to complete information about medications, 
we will ask patients about prescribed medication.
 Biomarkers
Physiological measurements of heart rate and blood pres-
sure will be measured using a calibrated Omron device 
(Ref: HEM-7114) and Standard Operating Procedure by 
trained healthcare professionals. Patients will sit quietly 
for 10 min before the examinations.
Blood LDL- C: Quantification of serum LDL will be 
performed using automated equipment by a direct 
method.
Recent large epidemiological studies confirmed that 
resting heart rate is an independent predictor of cardiovas-
cular mortality. Heart rate decrease is itself an important 
mechanism of the benefit of the blockers and other drugs 
that reduce heart rate after an acute myocardial infarc-
tion.1–4 Controversies on the optimal dose to obtain 
results remain, but the reduction in heart rate is noto-
rious in patients receiving beta- blockers.5 In Colombia, 
beta- blockers are a first- line drug used for secondary 
prevention. The most frequently used beta- blocker is 
carvedilol, which exhibits advantages in decreasing heart 
rate and mortality in patients with some type of cardiovas-
cular event.6
data management
Data will be stored on a secure system and will be pass-
word protected. All trial procedures will be performed in 
accordance with the principles of Good Clinical Practice 
(GCP). Essential documents of the sponsor/trial organ-
isers and investigators will be retained for at least 10 
years after completion of the trial. The research staff will 
maintain appropriate medical and research records for 
this clinical study and meet with the regulatory and insti-
tutional frameworks for the protection of the confiden-
tiality requirements. As sponsor of this trial, Fundación 
Cardiovascular de Colombia will allow regulatory agen-
cies to examine (under applicable law) clinical records to 
check the quality, safety and progress of the study.
statistical analysis
The main analyses will be an ‘intention to treat’, meaning 
it will compare all patients allocated to the intervention 
to patients allocated to the control arm, regardless of 
whether they received the allocated intervention. A sensi-
tivity per protocol analysis will also be performed. For 
continuous outcomes (including: LDL- C, blood pressure 
and heart rate), we will estimate an analysis of covariance 
model regressing the 12 month difference from baseline 
in the allocated group and the mean centred baseline 
values of the continuous variable. Deaths and hospital-
isations will be analysed using Cox regression models to 
estimate HRs. The assumptions underlying all of these 
models will be assessed. For subgroup analyses, we will 
only consider a limited number of variables that, given the 
mechanism of action of the intervention, could modify 
the effect of the intervention. A detailed statistical anal-
ysis plan setting out full details of the proposed analyses 
will be prepared and completed before the trial database 
is locked for final analysis. Missing data will be managed 
by an intention to treat analysis.
data monitoring
Data monitoring will be executed according to GCP 
Guidelines. This trial is a large, pragmatic, randomised 
controlled trial. The intervention is a strategy (SMS) to 
change behaviour and increase adherence of safe and 
proven effective interventions for secondary preven-
tion that have been in clinical use for decades. Clinical 
management for underlying conditions will remain as 
per hospital’s standard protocol. Based on these factors, 
the probability of harm or injury (physical, psychological, 
social or economical) occurring because of participation 
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in this research study was assessed as low risk to partic-
ipants in each of these categories. Based on the low 
risks associated with this trial, there will not be a data 
monitoring committee. However, a monitoring plan to 
ensure appropriate performance of the trial will be devel-
oped, which will incorporate 100% central monitoring 
in conjunction with procedures, such as investigator 
training and meetings and written guidance. All data will 
be subject to statistical monitoring, and at least 10% of 
data will be subjected to on- site monitoring. Investiga-
tors/institutions are required to provide direct access 
to source data/documents for trial- related monitoring, 
audits, ethics committee review and regulatory inspec-
tion. All trial- related and source documents must be kept 
for 15 years after the end of the trial.
Patient and public involvement
We did not directly include PPI in this study. However, 
to design the intervention, we interviewed patients 
about their perceptions of eHealth and their previous 
experience with mobile cellular phone technology and 
obtained their feedback about the messages in the inter-
vention. The Ethics Committee evaluated and approved 
our research included patient representatives.
EthICs And dIssEMInAtIon
Protocol amendments
We redefined systolic blood pressure and heart rate as 
secondary outcomes because we do not have calculation 
power for these measures. In the first version of protocol, 
these measures were primary outcomes.
Ethical considerations
The study will be performed in compliance with the 
protocol, regulatory requirements, GCP and the ethical 
principles of the Declaration of Helsinki.
Informed consent
The investigator or designated personnel will inform 
the patient of the objectives, methods, anticipated bene-
fits and potential risks and inconveniences of the study. 
The patient will be given every opportunity to clarify any 
points he/she does not understand and, if necessary, ask 
for more information. Written consent must be given by 
the patient and/or the legal guardian of the patient after 
detailed information about the study is provided in accor-
dance with any national provisions on the protection of 
clinical study patients. The verbal explanation will cover 
all of the elements specified in the written information 
provided to the patient. Patients and/or legal guardians 
will be required to sign and date the informed consent 
form. Patients who refuse to give or who withdraw written 
informed consent will not be included or continued in 
the study. The trial will include a ‘pre- selection’ informed 
consent, per law 1581 of 2012 and decree 1377 of 2013 
or law of protection of personal data, where the study 
team is authorised to handle personal and clinical data 
of the subject. Calls made in the pre- selection and phase 
2 visit will be recorded and stored for a set time. Eligible 
participants will only be included in the study after 
signing ‘txt2heart Colombia’ informed consent (testified, 
where required by law or regulation), as approved by the 
ethics committees. The process will be documented in 
the patient source documents, specifically in case report 
forms.
Confidentiality: Information about the study subjects 
will be kept confidential. The investigators will ensure 
the anonymity of patients, and patients will not be iden-
tified by name in any document. Informed consent 
forms and patient recruitment registration will be kept 
strictly confidential only to permit identification of the 
patient at Fundación Cardiovascular de Colombia. Infor-
mation about the study subjects will be handled under 
the laws and regulations of Colombia (Law 1581 of 2012 
and Decree 1377 of 2013, Law of data protection). The 
regulations that require an authorisation signed by the 
patient including the follow information: What protected 
health information (PHI) will be collected from the study 
subjects, who will have access to that information and 
why, who will use and disclose that information and the 
right to withdraw his/her authorisation to use their PHI.
Access to data
The principal investigator and sub- investigators will 
have access to the data to verify and analyse the results. 
To ensure confidentiality, all of the investigators will be 
blinded of participant identification.
Ancillary and post-trial care
Due to its low risk, the intervention in this trial will not 
include insurance for participants. However, we will refer 
patients to their medical services in case we think that 
they need assistance. Furthermore, a full explanation of 
the scope and limitations of the study will be told to the 
patients before they sign the informed consent.
dissemination policy
The txt2heart Colombia trial is aimed to provide high 
level evidence that evaluates whether SMS messages deliv-
ered through mobile telephones change the behaviour of 
Colombian patients who have suffered a cardiovascular 
event. Trial results will be presented to the health local 
authorities, and if the intervention is effective and safe, we 
hope this strategy will be implemented quickly because of 
its low cost and wide- reaching impact on the population.
The results from the trial will be published in an open 
journal to provide scientists, clinicians and policymakers 
access to the data.
limitations
Because, it is probably that most of patients will start the 
study already on statins, the LDL changes need to be 
evaluated with caution considering participants’ start 
point. Likewise, power calculation is based on pre versus 
post statin treatment, rather than on- therapy at base-
line changes. Regarding heart rate and blood pressure, 
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because there is not power calculation; comparing entry 
and exit measures is limited. Finally, adherence measures 
are limited because we will not establish a baseline and we 
must consider self- reported scales downsides.
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